Other Events ·
Roivant Sciences Ltd. announced that the U.S. Food and Drug Administration approved LISRAYA (brepocitinib) for the…
ROIVRoivant Sciences Ltd.
Roivant Sciences Ltd. announced that the U.S. Food and Drug Administration approved LISRAYA (brepocitinib) for the treatment of adults with dermatomyositis. The company launched the drug commercially immediately upon approval, approximately five weeks ahead of its previous guidance to address significant unmet medical need. The wholesale acquisition cost is set at $35,000 for a 30-count bottle of 30 mg tablets. Roivant operates in the biopharmaceutical industry, developing and commercializing treatments through its network of subsidiary companies.